References
- Ravi Kumar M. N. V, Handbook of Particulate Drug Delivery Volume II, American Scientific Publishers 332(2008).
- Nachum Z and Shupak A, "Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications", Clinical Pharmacokinetics, 45(6), 543(2006). https://doi.org/10.2165/00003088-200645060-00001
- Berner B and John V.A, "Pharmacokinetic characterisation of transdermal delivery systems", Clinical pharmacokinetics, 26(2), 121(2004).
- P. Jinks and K. Hunt, "Improving Suspension MDI Dose Consistency in Patient Use by Incorporation of a Novel Semi-Permeable System Component," in Proceedings of Drug Delivery to the Lungs XVII., 172(2006).
- 3M published patent applications, WO200662651 and WO2006/071512. C. Jewell, J. Heylings, H. M. Clowes, and F. M. Williams, Percutaneous absorption and metabolism of dinitrochlorobenzene in vitro. Arch Toxicol, 74, 356 (2000). https://doi.org/10.1007/s002040000123
- M. Wang, Y. Yang, and P. W. Heng, Skin permeation of physostigmine from acid-based formulations: evaluating the choice of solvent. Int. J. Pharm., 290, 25 (2005). https://doi.org/10.1016/j.ijpharm.2004.10.027
- Wilby M., "Increasing Dose Consistency of pMDIs," Drug Delivery Technol., 5(9), 59(2005).
- B. M. Magnusson, S. E. Cross, G. Winckle, and M. S. Roberts, Percutaneous absorption of steroids: determination of in vitro permeability and tissue reservoir characteristics in human skin layers. Skin Pharmacol. Physiol, 19, 336 (2006). https://doi.org/10.1159/000095254
- Papakostas G.I., "Tolerability of modern antidepressants". J Clin Psychiatry Suppl. 69(2) 8(2008). https://doi.org/10.4088/JCP.0308e08
- Haddad P., "Antidepressant discontinuation syndromes". Drug Saf., 24(3), 183(2001). https://doi.org/10.2165/00002018-200124030-00003
- R. Ramasubbu, "Antidepressant treatment-associated behavioural expression of hypomania: a case series". Prog. Neuropsychopharmacol. Biol. Psychiatry, 28(7), 1201(2004). https://doi.org/10.1016/j.pnpbp.2004.06.015
- C. Amnuaikit, I. Ikeuchi, K. Ogawara, Higaki, K., and T. Kimura, Skin permeation of propranolol from polymeric film containing terpene enhancers for transdermal use, Int. J. Pharm., 289, 167 (2005). https://doi.org/10.1016/j.ijpharm.2004.11.007
- S. W. Stein and J. S. Stefely, "Reinventing Metered Dose Inhalers: From Poorly Efficient CFC MDIs to Highly Efficient HFA MDIs," Drug Delivery Technol., 3(1), 46(2003).
- S. Mutalik, and N. Udupa, Transdermal delivery of glibenclamide and glipizide : in vitro permeation studies through mouse skin, Pharmazie., 12, 838(2002).
- T. E. K Murthy, and V. S. Kishore., Effect of casting solvent on permeability of antihypertensive drugs through RS 100 films, Asian J Pharm. 1, 108(2002).
- Sher et al., "Adhesives Having a Microreplicated Topography and Methods of Making and Using Same," US Patent 6,197,397, (2001).
- J. Sandt, J. A. Van Burgsteden, S. Cage, P. L., Carmichael, Dick I, Kenyon S, Korinth G, and Larese F., In vitro predictions of skin absorption of caffeine, testosterone, and benzoic acid: a multi-centre comparison study. Regul. Toxicol. Pharmacol, 39(3), 271 (2004). https://doi.org/10.1016/j.yrtph.2004.02.004
- A. Fini, V. Bergamante, G. C. Ceschel, C. Ronchi, and De Moraes CA, Control of transdermal permeation of hydrocortisone acetate from hydrophilic and lipophilic formulations. AAPS. Pharm. Sci. Tech., 9(3), 762 (2008). https://doi.org/10.1208/s12249-008-9107-z
- M. Shevachman, N. Garti, and A. Shani, Enhanced percutaneous permeability of diclofenac using a new U-type dilutable microemulsion, Drug Dev. Ind. Pharm., 34, 403 (2008). https://doi.org/10.1080/03639040701662479
- J. Novotny, P. Kovarikova, M. Novotny, B. Janusova, A. Hrabalek, and K. Vavrova, Dimethylamino acid esters as biodegradable and reversible transdermal permeation enhancers: effects of linking chain length, chirality and polyfluorination, Pharm. Res., 26, 811 (2009). https://doi.org/10.1007/s11095-008-9780-3